Embark on a two-year hands-on training that enables fellows to support prevention, preparedness and surveillance activities, outbreak investigation and control of communicable disease threats across the European Union and European Economic Area (EU/EEA) – and beyond. Apply for the ECDC Fellowship Programme (EPIET/EUPHEM) by 15 October 2023.
The Emerging Viral Diseases-Expert Laboratory Network (EVD-LabNet) is organising a training course on “Introduction to virology, diagnostics and molecular epidemiology on emerging and vector-borne disease viral pathogens”.
The Emerging and Vector-borne Diseases (EVD) team of ECDC communicates, consults and cooperates with EVD-Net on surveillance, response, prevention, control and preparedness aspects of EVDs and vectors, with particular focus on country needs and country support possibilities.
This report presents the results of the first external quality assurance (EQA) scheme for B. pertussis antimicrobial susceptibility testing by ECDC as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) consortium.
This report presents the results of the first external quality assessment (EQA) scheme for Bordetella pertussis vaccine antigen expression, pertactin (PRN), pertussis toxin (PT) and filamentous haemagglutinin (FHA) by the European Centre for Disease Prevention and Control (ECDC) as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) activities.
Infection with Salmonella spp. is the second most reported zoonotic disease in humans with 60 050 reported cases in 2021 in the European Union (EU) and Salmonella is associated with the highest number of foodborne outbreaks. The overall EU trend of salmonellosis incidence for the years 2017 to 2021 have not changed significantly. To prevent foodborne diseases such as salmonellosis, human surveillance systems at different levels are essential to monitor the disease and to have an early detection and response to outbreaks.
This core protocol for ECDC studies of vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or with influenza, version 2.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with Severe Acute Respiratory Infection (SARI), already published as version 1.0.